Business Wire (press release)Gene Therapy Looks Promising for Transfusion-Dependent β-ThalassemiaMonthly Prescribing ReferenceA majority of patients with transfusion-dependent β-thalassemia (TDT) were able to achieve freedom from chronic blood transfus… Continue reading
CNBCThese former SpaceX engineers are helping scientists find cures for genetic diseasesCNBCBiology is undergoing a huge shift, as researchers now have a new tool to alter our genetic code. Advances in a technology called CRISPR — which stands for Clu… Continue reading
New York Times |
The Problem With Miracle Cancer Cures
New York Times A recent analysis estimated that about 15 percent of patients with advanced cancer might benefit from immunotherapy — and it’s all but impossible to determine which patients will be the lucky ones. Just last week, a study of lung cancer patients … Hellman Expands on TMB Testing in Lung CancerOncLive |
Regulatory Focus |
Recon: Bluebird’s gene therapy eliminates blood transfusions for some beta-thalassemia patients
Regulatory Focus … AI pharma start-up BenevolentAI now worth $2 billion after $115 million funding boost (CNBC) (TechCrunch) (Reuters) (Business Insider) (Endpoints); Kleiner Perkins’ Beth Seidenberg bumps Tmunity’s cell therapy round to $135M (Endpoints) (Fierce … |
Endpoints News |
Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in …
Endpoints News San Diego-based Tocagen $TOCA has inked a licensing deal with ApolloBio, giving an affiliate of the Beijing-based company an exclusive license to develop and commercialize its cancer-selective immunotherapy. Tocagen’s treatment, called Toca 511 & Toca … Tocagen (TOCA) Reports License Agreement with Beijing Apollo …StreetInsider.com |
Endpoints News |
Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in …
Endpoints News San Diego-based Tocagen $TOCA has inked a licensing deal with ApolloBio, giving an affiliate of the Beijing-based company an exclusive license to develop and commercialize its cancer-selective immunotherapy. Tocagen’s treatment, called Toca 511 & Toca … Tocagen (TOCA) Reports License Agreement with Beijing Apollo …StreetInsider.com |